Mastering DLCO for COPD: MKSAP Insights

Let’s talk about the Diffusing Capacity of the Lung for Carbon Monoxide, or DLCO, in the context of general internal medicine—especially as it relates to chronic obstructive pulmonary disease, or COPD. Memorizing the key facts and mechanisms about DLCO can help you differentiate patient presentations, predict prognosis, and tailor management for COPD. Here’s how to drill these concepts for high retention.

DLCO measures how well oxygen and other gases transfer from the alveoli into the bloodstream. The test uses carbon monoxide because its high affinity for hemoglobin allows a sensitive gauge of the lung’s ability to transfer gas. In clinical practice, a DLCO below 55 percent of predicted is a critical threshold for COPD patients: it signals a higher risk for arterial oxygen desaturation during exercise.

The mechanism here is straightforward. When the alveolar-capillary membrane is thickened or destroyed—as in emphysema—the surface area for gas exchange drops, and so does DLCO. When DLCO falls below 55 percent of predicted, the lungs can’t effectively transfer oxygen during increased demand, like during exercise. This desaturation can be dangerous, and it’s a key reason why DLCO matters in evaluating COPD severity.

You can remember “55” as the cutoff with an easy mnemonic: “DLCO, Don’t Let CO fall Below Fifty-Five.” If the DLCO is above 55 percent of predicted, exercise-induced desaturation is almost entirely excluded. Owens and colleagues reported that a diffusing capacity above this level was 100 percent specific for ruling out desaturation during exercise in COPD.

DLCO does more than just predict desaturation. It also correlates with the frequency of COPD exacerbations. Patients with frequent exacerbations have a mean DLCO percentage predicted that’s 7.2 percent lower than those who don’t exacerbate as often. This means that a low DLCO isn’t just a static number—it tracks with how unstable the disease is. The mechanism is likely the same: reduced surface area for gas exchange increases the risk of hypoxemia and may trigger exacerbations.

There’s also a sex difference in DLCO decline. Women with COPD experience a more rapid drop in DLCO over time compared to men. This was demonstrated by Casanova and colleagues, who found that the slope of decline is steeper in female patients, suggesting a sex-specific aspect to COPD progression. The cause of this faster decline in women isn’t fully understood, but it may relate to differences in how lung tissue responds to injury, or to hormonal or anatomical factors.

Historically, the measurement of DLCO evolved through key milestones. In 1964, Ayres and a team developed the rebreathing carbon monoxide method to measure DLCO. They found that in obstructive emphysema, loss of diffusing surface isn’t always the main reason for low oxygen saturation—meaning that other mechanisms like ventilation-perfusion mismatch also contribute. This helps explain why not all patients with low DLCO are hypoxemic at rest.

By 1984, Owens and colleagues solidified DLCO’s role by showing it’s a more specific and sensitive predictor of exercise-induced arterial desaturation in COPD than FEV1, the classic spirometry marker. In other words, spirometry alone can miss patients at risk during exertion, while DLCO picks them up.

In 2019, Balasubramanian and collaborators highlighted that DLCO is still inconsistently used in assessing COPD. This matters because relying on spirometry alone can miss both the prognostic and management value of a low DLCO. They emphasized the importance of DLCO as an adjunct to spirometry, especially for understanding disease severity, predicting outcomes, and individualizing therapy.

Emphysema subtypes also influence DLCO decline rates. Centrilobular emphysema, or CLE, is much more strongly associated with longitudinal declines in DLCO and increased mortality in COPD patients than paraseptal emphysema, or PSE. CLE tends to destroy large areas of alveolar walls, slashing the surface area for gas exchange. In contrast, PSE affects the edges of the pulmonary lobules, often sparing more of the gas exchange interface. For high-yield learning, remember: “CLE kills DLCO, PSE preserves.”

Low DLCO is one of the strongest predictors of mortality in COPD. A meta-analysis found that non-survivors had a DLCO predicted percentage 12.44 percent lower than survivors. This is a larger gap than the 7.2 percent difference seen between frequent and infrequent exacerbators. The mechanism is direct: low DLCO means less gas exchange, more chronic hypoxia, and greater risk of life-threatening complications.

The importance of remembering exact DLCO values is clear. To cement this for exams and clinical use, use the following mnemonic chain: “Fifty-Five—Stay Alive, Seven Down—More Around, Twelve Down—Going Underground.” The first is the 55 percent desaturation rule, the second is the mean 7.2 percent difference with frequent exacerbations, and the third is the 12.44 percent difference in non-survivors.

Let’s add a clinical pearl: DLCO testing isn’t always routine in COPD, despite its value. Balasubramanian and team noted the added benefit of DLCO testing beyond common tools like spirometry is still under-recognized. That means you may encounter COPD patients without a DLCO on file, representing a missed opportunity for risk stratification and tailored interventions.

To remember the sequence of key historical advances in DLCO, use “Ayres in ’64, Owens in ’84, Balasubramanian in 2019, Casanova in 2021.” Ayres brought the rebreathing CO method, Owens proved DLCO’s predictive power for desaturation, Balasubramanian called for more DLCO use in COPD assessment, and Casanova identified faster DLCO decline in women.

When you see a COPD patient with centrilobular emphysema, recall the direct link to accelerated DLCO decline and higher mortality. Centrilobular changes mean more alveolar wall loss and less surface area for gas transfer, driving the DLCO down more quickly than other emphysema subtypes.

The DLCO test itself involves the patient inhaling a small amount of carbon monoxide and holding their breath for about ten seconds. The amount of CO that disappears from the exhaled air tells you how much transferred into the blood. This is sensitive to both alveolar surface area and capillary blood volume, so diseases like pulmonary fibrosis (which thickens the membrane) or pulmonary hypertension (which reduces blood flow) can also lower DLCO, but in COPD, emphysematous destruction is the key driver.

Every time you note a DLCO result, ask yourself three things: Is it below 55 percent, suggesting desaturation risk? Is it lower than expected for a given FEV1, which may signal more advanced emphysema? Is there evidence of rapid decline, especially in female patients or in those with centrilobular emphysema?

Non-invasive, repeatable, and highly informative, DLCO is a test whose numbers—particularly 55, 7.2, and 12.44—can guide clinical decisions, prognostication, and patient counseling.